Previous 10 | Next 10 |
home / stock / bmy / bmy articles
The past week’s earnings were bordering on the negative, impacting trader sentiment, and the focus now shifts to the unfolding week that woul...
Tuesday, the FDA announced to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the ...
Bristol Myers Squibb & Co (NYSE:BMY) and Exelixis Inc (NASDAQ:EXEL) revealed four-year follow-up results from a cancer study that compared o...
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell ca...
BALA CYNWYD, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and...
Saturday, Bristol-Myers Squibb Company (NYSE:BMY) released results from the Phase 3 CheckMate -8HW trial evaluating Opdivo (nivolumab) pl...
Thursday, Ikena Oncology Inc (NASDAQ:IKNA) announced an organizational streamlining to reallocate resources from exploratory research and...
Diabetes treatments such as Ozempic and Mounjaro became the blockbuster drugs of 2023 thanks to their popularity as weight-loss remedies. Prices fo...
Medicare Part D beneficiaries facing rising drug costs received welcome news as changes brought about by the 2022 Inflation Reduction Act cap their...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
Bristol-Myers Squibb Company Website:
NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb Company Our Approach to ESG At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development a...
The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: ...
SBTi validation affirms BMS' long-standing commitment to environmental stewardship PRINCETON, NJ / ACCESSWIRE / July 18, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), ...